Radiation Oncology

EGFR+

Questions discussed in this category

How do you counsel patients with Stage IIIA EGFR+ lung cancer regarding treatment intent with concurrent chemoRT + consolidative systemic therapy?

With low #s of patients on the durvalumab PACIFIC trial with EGFR mutated disease, and LAURA trial design of osimertinib until progression, should we ...

3 Answers available

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

2 Answers available

What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?

Do you consider dose escalating to 160 mg or do you add chemotherapy to osimertinib?

1 Answer available

How many days do you hold osimertinib during or around SBRT for oligometastatic EGFR mutated advanced lung cancer?

Does the site of treatment factor into your decision?

2 Answers available

Should osimertinib be held prior to yttrium 90 liver directed therapy?

1 Answer available

How do you approach EGFR mutated NSCLC with isolated progression in the chest who is planned for a course of radiation at least 3-4 weeks?

How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?

1 Answer available

In locally advanced EGFR-mutated NSCLC with initial good response to osimertinib, how do you manage local progression of the primary?

Would you consider SBRT and continue osimertinib?

2 Answers available

Is PORT recommended for incidentally found N2+ NSCLC after lobectomy for oligoprogressive metastatic NSCLC?

Does EGFR+ status influence your decision? What is the significance of this finding and its potential for progression? Is it simply occult disease con...

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Clin Oncol (R Coll Radiol), 2017 Nov 16

Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06

Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.

Radiother Oncol, 2020 Jul 31

An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011-10-01

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).

Lung Cancer, 2020 Nov 13

Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.

Neuropathology, 2019 Mar 13

Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: An autopsy report.

Respir Investig, 2014 Nov 13

Disease flare after gefitinib discontinuation.

JTO clinical and research reports, 2022 Apr 21

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.

The New England journal of medicine, 2023 Nov 08

Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.

The New England journal of medicine, 2024 Jun 02

Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC.

The New England journal of medicine, 2018-01-11

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Related Topics in Radiation Oncology